Literature DB >> 22297016

Strategic patient education program to prevent catheter-related bloodstream infection.

Rebecca F DeLa Cruz1, Brenda Caillouet, Susan S Guerrero.   

Abstract

Central venous catheters (CVCs) are used commonly for venous access during treatment, and catheter-related bloodstream infection (CRBSI) is a frequent, yet highly preventable, hospital-acquired infection. One of the performance elements of the Joint Commission's 2012 National Patient Safety Goals addresses the education of patients and family members on CVC care and management, as well as CRBSI prevention before a central catheter is inserted. This article presents the history and roles of the Infusion Therapy Team at the University of Texas MD Anderson Cancer Center in CVC care and describes an organized patient education program that plays a key part in the institution's strategy to reduce and prevent CRBSI. Institutional standard policies and procedures for patient care should be in compliance with guidelines of the Centers for Disease Control and Prevention and the Joint Commission before any patient educational initiative is implemented. Such standards will serve as a guide to set up, organize, and implement an effective program.

Entities:  

Mesh:

Year:  2012        PMID: 22297016     DOI: 10.1188/12.CJON.E12-E17

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  3 in total

1.  Infection prevention requirements for the medical care of immunosuppressed patients: recommendations of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute.

Authors: 
Journal:  GMS Hyg Infect Control       Date:  2022-04-13

2.  The Impact of Open versus Closed Catheter Access System of Central Venous Catheter on Infection Prevention in Critically Ill Patients: A Comparative Evaluation.

Authors:  Davinder Kaur; Surinder Jaspal; Sukhminderjit Singh Bajwa
Journal:  Iran J Nurs Midwifery Res       Date:  2020-11-07

3. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-02       Impact factor: 1.513

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.